Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Jun 2025.
- Notable investors include Imperial College London, Institute for Follicular Lymphoma Innovation, Karolinska Institutet Holding, Sintef Group, Utrecht University — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NanoCell Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoCell Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoCell Therapeutics
Developer of a novel cell-directed, lipid-enabled, DNA-based CAR-TCR therapy platform, designed to make cell-engineered therapies more affordable, scalable and accessible for a broader patient population. The company's platform integrates DNA into the target cell's genome to achieve durable efficacy, addressing the limitations of temporary RNA-based therapies for non-viral platforms, featuring cell-directed lipid nanoparticles (LNPs), designed to modify T cells for CAR and TCR therapy, enabling existing cell and gene therapy companies to improve accessibility, clinical potential and cost efficiency.
- Sector
- Healthcare
- HQ
- Wayne, PA, United States
- Founded
- 2021
- Employees
- 16
- Website
- nanocelltx.com/
- Ownership
- Privately Held (backing)
NanoCell Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoCell Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoCell Therapeutics in its N-PORT filings yet. We sweep new filings monthly.